Trium Capital’s Blueprint Medicines BPMC Stock Holding History

Trium Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-240,099	Closed	-$30.8M	–	56
2025 Q2	$30.8M	Buy	+240,099	New	+$24.9M	7.66%	4

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Trium Capital's BPMC Position: Q3 2025 in Review

Trium Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 240,099 shares — an estimated $30.8M sold.

Trium Capital first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $30.8M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Trium Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Trium Capital sold 240,099 Blueprint Medicines shares in Q3 2025, an estimated $30.8M.
Trium Capital first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Trium Capital's Blueprint Medicines position peaked at $30.8M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Trium Capital's 13F filing for Q3 2025, filed 16 Oct 2025.